Peel Therapeutics has commenced a first-in-human Phase I clinical trial of its small molecule nanoparticle, PEEL-224, in advanced solid tumour patients. 

The latest development comes after the US Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application submitted by the company. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A new inhibitor of topoisomerase I, PEEL-224 is intended to treat cancer. 

The dose escalation, multicentre, repeat-dose, open-label trial will enrol advanced solid tumour patients to assess the safety, tolerability, pharmacokinetics and initial antitumor activity of PEEL-224.

According to preclinical findings collected so far, PEEL-224 showed to be a promising therapy with a lasting complete response in the most aggressive solid tumours for over six months.

See Also:

Its molecular structure stops its efflux from cancer cells through the ABCG2 multidrug transporter pump, indicating the reduced likelihood of tumours becoming resistant to PEEL-224.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, it helps in overcoming irinotecan resistance due to this property.

Last year, the company closed a convertible note financing of $18m. 

Till date, Peel Therapeutics raised $30m in oversubscribed note rounds and small business awards from the start.

Peel Therapeutics CEO and co-founder Joshua Schiffman said: “We are very encouraged by the preclinical data seen in multiple solid tumour types. 

“Our company looks forward to further evaluation of PEEL-224 in patients, bringing us closer to our goal of delivering safer and more effective cancer therapy.”

The company is focusing on progressing a therapeutic pipeline for treating various devastating conditions, with a current focus on cancer and inflammation.

Peel Therapeutics is a member of the Utah life sciences industry collective, BioHive.